Mitem Pharma acquired from Novartis worldwide rights to Desferal, commonly used to lower excessive iron levels induced by ...

Columnist Mary Shaniqua, returning from her post-wedding activities, has learned that stepping back from advocacy obligations ...

The stroke rate among adults and children with sickle cell disease in the U.S. is rising, indicating a need for greater ...

Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.

As a health professional and sickle cell patient, I’m constantly driven to create awareness about the disease. My motivation transcends professional duty; it’s a personal quest to make a difference.